Rapid diagnostics first, then revolutionary antibiotics will follow
This article was originally published in Clinica
Executive Summary
Rapid diagnostics that can be used to identify the right study patients, enrich clinical trials, improve clinical care and stewardship, and help get drugs approved for limited populations will be an essential factor to reinvigorating the antibiotic pipeline and quelling the tide of multi-drug resistant infections, stakeholders echoed over and over again at a recent workshop organized by the National Institutes of Health and the US FDA.